Ichor Biologics specializes in the development of therapeutic monoclonal antibodies to treat infectious diseases. Our company has developed a platform for characterizing and isolating pathogen-specific antibodies from convalescent patients. This platform allows us to preserve neutralizing and non-neutralizing antibody functions, thereby increasing the likelihood of in-vivo efficacy. Our initial disease targets include viral infections, such as Hantaviruses and HBV.
No products posted yet
No services posted yet
This data is part of our proprietary analytics report:
This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality